Frontier mental health research: psychedelics & drug studies

Key findings

• The strongest clinical evidence for MDMA-assisted therapy is for PTSD, not for ordinary sadness or low mood. ^{15063 15135 15078}
• MDMA-assisted psychotherapy means giving MDMA together with structured therapy sessions before and after the drug experience. ^{15063 15086 15065}
• For depression or general low mood, only small or early-stage studies exist so far. These suggest possible benefit but are not conclusive. ^{15091 15070 15086}
• MDMA is mainly an 'entactogen' — it boosts serotonin and tends to increase social openness and the ability to recall emotional memories, rather than causing classic psychedelic hallucinations. ^{15086 15091}
• Clinical trials done in controlled medical settings generally reported acceptable short-term safety, but long-term risks and rare harms are not fully known and regulators have not approved MDMA for broad psychiatric use. ^{15135 15078 15091}
• How the treatment is given matters a lot: preparation, the physical setting, trust in the therapist, and follow-up therapy strongly shape outcomes and safety. ^{15065 15086 15063}
• Researchers have not found a clear change in a common blood marker of brain growth (BDNF) after so‑called psychoplastogen drugs, which means simple blood tests are not yet reliable signs of treatment effects. ¹⁵¹²⁹
• Many studies are small, use different methods, and often include mostly white participants, so we cannot be sure results apply to everyone or to normal clinical settings. ^{15064 15095 15087}